Tevogen Bio
高管
查看带有其 16 名主要高管的组织结构图
Tevogen Bio 搜索最多的简介
- Ryan Saadi, Chairman of the Board and Chief Executive Officer
- Lindee Goh, Director
- Curtis Patton, Director
高管在Tevogen Bio变化
- Tapan Shah已作为Head of Investor Relations and Corporate Development加入公司 (新闻发布的2024四月5号).
- Mittul Mehta已作为Chief Information Officer and Head of Tevogen.ai加入公司 (新闻发布的2023十月24号).
创建提醒
跟踪 Tevogen Bio 的高管变动
生物技术
Tevogen Bio 拥有 2,293 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Merck has announced the acquisition of EyeBio (公布2024五月31号).
- Actuate Therapeutics 刚刚宣布为 50 筹款数百万美元。 (公布2024五月29号).
- Grey Wolf Therapeutics 刚刚宣布为 50 筹款数百万美元。 (公布2024五月25号).
生物技术 行业的其他推荐联系人
消息
Tevogen Bio 的最新新闻稿
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
- Tevogen Bio Reports First Quarter 2024 Financial Results
- https://twitter.com/tbsnewsbd
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Tevogen Bio Reports Series A-1 Preferred Stock Investment
- Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
- Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
- View more press releases Close
关于 Tevogen Bio 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Ryan Saadi 
